Get the Stockscreener App
1.06
0.95%
0.01
After Hours:
1.05
-0.01
-0.94%
Fibrobiologics Inc stock is traded at $1.06, with a volume of 60,507.
It is up +0.95% in the last 24 hours and down -25.35% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.05
Open:
$1.04
24h Volume:
60,507
Relative Volume:
0.15
Market Cap:
$5.52M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.1433
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
-1.85%
1M Performance:
-25.35%
6M Performance:
-80.52%
1Y Performance:
-93.46%
1-Day Range:
$1.02
$1.0929
1-Week Range:
$1.0016
$1.0929
52-Week Range:
$0.9523
$19.80
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.06 | 5.47M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
Fibroblast cell therapy avoided psoriasis relapse in FibroBiologics mouse study - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FBLG Stock Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
New oral cell therapy platform aimed at gut diseases from IBS to Crohn's - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics | DEFA14A: Others - Moomoo
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Jason - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer GARCIA RUBEN A - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer O'HEERON PETE - Moomoo
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com South Africa
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):